We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Regular Dose of Aspirin To Reduce Risk of Inherited Bowel Cancer
News

Regular Dose of Aspirin To Reduce Risk of Inherited Bowel Cancer

Regular Dose of Aspirin To Reduce Risk of Inherited Bowel Cancer
News

Regular Dose of Aspirin To Reduce Risk of Inherited Bowel Cancer

Credit: Unsplash
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Regular Dose of Aspirin To Reduce Risk of Inherited Bowel Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

The international trial - known as CAPP2 – involved patients with Lynch syndrome from around the world and revealed that two aspirins a day, for an average of two and a half years, reduced the rate of bowel cancer by half.

The study, led by experts at the Universities of Newcastle and Leeds, published in The Lancet today, is a planned double-blind 10 year follow–up, supplemented in more than half of recruits with comprehensive national cancer registry data for up to 20 years.

Supports national guidance


The findings of the study further strengthens the National Institute for Health and Care Excellence (NICE)  recommendation on taking daily aspirin for those at high risk and supports wider use of aspirin to prevent cancer.

Based on the preliminary five year data from the CAPP2 trial, NICE recommended that aspirin should be offered for the prevention of bowel cancer in adults with Lynch syndrome.

Professor Sir John Burn, from Newcastle University and Newcastle Hospitals NHS Foundation Trust, who led the research, said the new findings further support this important guidance.

He said: “I had an idea 30 years ago that people with a genetic predisposition to colon cancer could help us to test whether aspirin really could reduce the risk of cancer.

“Patients with Lynch syndrome are high risk and this offered statistical power to use cancer as an endpoint - they are like the canaries in the mine who warned the miners that there was gas.

“It took a long time to start the trial and to recruit enough people in 16 countries, but this study has finally given us an answer.

“Two aspirins a day for a couple of years gives protection that lasts more than 10 years and the statistical analysis has become much stronger with time.

“For people at high cancer risk, the benefits are clear – aspirin works. Our new international trial, CaPP3, will see if smaller doses work just as well.”

Findings showed that when all original recruits were included in the study, those on aspirin had 42% fewer colon cancers.  Among those who took the aspirin for a full two years, there were 50% fewer colon cancers.

The study involved 861 patients with Lynch syndrome, which affects about one in 200 people in the population. These people have a genetic problem with DNA repair, making them at much higher risk of cancers such as bowel and womb.

A group of 427 were randomised to aspirin continuously for two years and 434 were allocated to a placebo and then they were all followed for 10 years. Out of those given two aspirins each day (600mg) there were 18 fewer colon cancers, representing a drop of 42.6%.

When all 163 Lynch syndrome cancers are included in the analysis – such as cancer of the endometrium or womb - there was an overall reduced risk of cancer of 24% in those taking aspirin, or 37% in those who took aspirin for the full two years.

Reference: Burn, et al. (2020) Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. The Lancet. DOI: https://doi.org/10.1016/S0140-6736(20)30366-4. 

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement